Bacil Pharma Ltd, a active public limited company, was established on 08 May 1987 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: L24200MH1987PLC043427. Registered under ROC Roc Mumbai. it is listed on BSE: 524516. It has an authorized capital of ₹20.00 Cr and a paid-up capital of ₹14.99 Cr.
It upholds a compliant status. In 2023, it reported revenue of ₹1.15 M and a net worth of ₹1.10 Cr. Its leadership includes Dinesh Chander Notiyal (Director), Avani Savjibhai Godhaniya (Director), Chaitali Kalpataru Shah (Additional Director). Past directors included Man Mohan Ghildyal, Dinesh Chander Notiyal, Lal Lachhmandas Hingorani. Its latest AGM occurred on 27 September 2024, with the balance sheet filed on 31 March 2024. It is based at Office G2/G3, Samarpan Complex, Next To Mirador Hotel,, Link Road, Opp Satam Wadi, Chakala, Sahar, Andheri (East),, Mumbai, Maharashtra, 400099.
L24200MH1987PLC043427
043427
08 May 1987
₹20.00 Cr
₹14.99 Cr
Roc Mumbai
Listed (BSE: 524516)
Active
Explore comprehensive insights into Bacil Pharma Ltd — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dinesh Chander Notiyal | Director | 28 Aug 2024 | Current |
| Avani Savjibhai Godhaniya | Director | 28 Aug 2024 | Current |
| Chaitali Kalpataru Shah | Additional Director | 16 Jul 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Manager | 16 Sep 2023 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2024 | Past |
| Pramod Abcsdd | Director | 24 Feb 2012 | Past |
| Pramod Abcsdd | Additional Director | 26 Sep 2024 | Past |
| Pramod Abcsdd | Director | 31 Aug 2024 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bacil Pharma Ltd, for the financial year ended 2023, experienced significant growth in revenue, with a 99.07% increase. The company also saw a substantial improvement in profitability, with a 97.36% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.2%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, Bacil Pharma had a promoter holding of 42.67% and a public holding of 57.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Bacil Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Bacil Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bacil Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Chaitali Kalpataru Shah was appointed as a Cfo was appointed as a Cfo on 12 Aug 2025 & has been associated with this company since 4 months 16 days . was documented.
The activity Chaitali Kalpataru Shah was appointed as a Additional Director was appointed as a Additional Director on 16 Jul 2025 & has been associated with this company since 5 months 12 days . was completed.
Progress on Bacil Pharma Ltd last Annual general meeting of members was held on 27 Sep 2024 as per latest MCA records. was documented.
The activity Dinesh Chander Notiyal was appointed as a Director was appointed as a Director on 28 Aug 2024 & has been associated with this company since 1 year 4 months . was completed.
Progress on Avani Savjibhai Godhaniya was appointed as a Director was appointed as a Director on 28 Aug 2024 & has been associated with this company since 1 year 4 months . was documented.
The activity Bacil Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was completed.
The CIN of Bacil Pharma Ltd is L24200MH1987PLC043427.
Bacil Pharma Ltd is headquartered at Office G2/G3, Samarpan Complex, Next To Mirador Hotel,, Link Road, Opp Satam Wadi, Chakala, Sahar, Andheri (East),, Mumbai, Maharashtra, 400099.
Bacil Pharma Ltd was incorporated on 08 May 1987.
The current directors of Bacil Pharma Ltd are
The primary industry of Bacil Pharma Ltd is Pharma.
Bacil Pharma Ltd is listed. It is listed on BSE: 524516.
The authorized capital of Bacil Pharma Ltd is ₹20.00 Cr, and the paid-up capital is ₹14.99 Cr.
The compliance status of Bacil Pharma Ltd is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX